Q2 ahead of expectations; like peers, there's no change to guidance
06/08/26 -"Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. Despite challenges in US immigration ..."
Pages
66
Language
English
Published on
06/08/26
You may also be interested by these reports :
06/08/26
Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. ...
06/08/26
CZM’s Q3 results exceeded expectations, with top-line growth driven by strong performance in Microsurgery. Ophthalmology showed modest growth. The ...
06/08/26
FMC delivered better-than-expected Q2 26 results on revenue and adjusted EBIT, though the margin beat was heavily reimbursement-driven and ...
05/08/26
Fresenius delivered a strong Q2, with adjusted EBIT and core EPS coming in comfortably ahead of expectations and revenue broadly in line. The beat ...